12. COST-UTILITY ANALYSIS OF THE USE OF PEMBROLIZUMAB AS POST NEPHRECTOMY ADJUVANT TREATMENT IN ADULT SUBJECTS WITH RENAL CELL CARCINOMA IN THE ITALIAN CONTEXT

[featured_image]
Download
Download is available until [expire_date]
  • Versione
  • Download 0
  • Dimensioni file 587.09 KB
  • Conteggio file 1
  • Data di creazione Gennaio 7, 2025
  • Ultimo aggiornamento Gennaio 7, 2025

12. COST-UTILITY ANALYSIS OF THE USE OF PEMBROLIZUMAB AS POST NEPHRECTOMY ADJUVANT TREATMENT IN ADULT SUBJECTS WITH RENAL CELL CARCINOMA IN THE ITALIAN CONTEXT

Università Tor Vergata, CEIS-Economic Avaluation and HTA (EEHTA) Via Columbia 2, 00133 Rome, Italy

segreteria.rome@isporitaly.org

Linkedin

©Copyright 2025 | ISPOR Italy – Rome Regional Chapter | C.F. 97803280581 | Privacy Policy